Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Michael David Lawlor

Steven Richard Brunette

Bryan Patrick McKibben

Rene Marc Lemieux

Craig Andrew Miller

Matt Aaron Tschantz

Jennifer A Kowalski

Joshua Courtney Horan

Hui Yu

Eugene R Hickey

Weimin Liu

Neil Moss

Derek Cogan

Zhaoming Xiong

Zhidong Chen

Donghong Amy Gao

Alexander Heim-Riether

Jin Mi Kim

Joerg Bentzien

René Marc Lemieux

Antonio J M Barbosa

Antonio J M Barbosa, Jr

Yang Yu

Antonio Jose Del Moral Barbosa, Jr

Joerg Martin Bentzien

Bryan Mckibben

Donghong A Gao

Antonio Jose Del Moral Barbosa

Antonio JM Barbosa

Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

[object Object]

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides

Disclosed are novel compounds of formula (I): wherein X, Y, R, Rand Rare as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Pyrimidine derivatives useful as inhibitors of PKC-theta

Growing community of inventors

Seymour, CT, United States of America

Michael David Lawlor